Call for consensus in defining biological aging

We speak with a key contributor to the Longevity2020 online conference about biological aging.

UK start-up AgeCurve is focused on the measurement of aging and claims to be the first start-up to use direct-to-consumer personal proteomics to provide deep age profiles to end users. AgeCurve’s founder and director Attila Csordas is a Longevity biologist and philosopher with expansive ideas on biological aging.

His company is also developing a targeted proteomics COVID-19 home saliva test which can accurately detect presence of COVID-19 proteins in saliva by measuring peptide ions distinct to the COVID-19 proteins.

Longevity.Technology: Attila’s also a curator on Monday 27th April to the Longevity2020 session on ‘Defining biological aging’ alongside speakers such as Aubrey de Grey, Nir Barzilai and Lynne Cox.



In the session we’ll be addressing the need for candidate definitions from different, biological, clinical, logical and computational angles to adopt a consensus definition for biological aging.

How are traditional biomarkers like body composition, muscle strength and cognition complimented by the techniques of methylation, inflammation and epigenetic?


With so many opinions and options: how can scientists prove their technologies and investors invest with confidence? We’ll be using this session to assist in directing many of the other sessions taking place on Longevity2020.

This event is free and you can pre-register here.

Image credit: AgeCurve

Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

Evidence for tenth hallmark of aging increases with new paper

Is ten the new nine? Additional research adds weight to the argument that extracellular matrix stiffening should be considered the tenth hallmark of aging. Since...

Help us help you: Longevity biotech survey

A new survey on translational processes and hurdles to clinical trials in Longevity biotech. We're working with two MDs: Oliver Zolman and Jian Fransen, on...

First Longevity announces first investors for current round

Some news of our own: European VC fund and a Longevity innovator participate in the First Longevity funding round. Last week we announced that Tom...

GDF15 protects from age‐related metabolic phenotypes

A recent study shows an important role for GDF15 in preventing aging-induced metabolic phenotypes by modulating systemic inflammatory responses in humans and mice. Dysfunction of...